Transition Metal Complexes in Cancer Therapy: Beyond Platinum
A Special Issue of Molecules (ISSN 1420-3049) belonging to the section "Cross-Field Chemistry".
Deadline for manuscript submissions: closed (31 July 2026) | Viewed by 1201
Editor
Interests: anti-cancer drug; biomimetic enzymatic reactions; catalysis; mechanism; transition metal complexes
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Transition metal complexes have transformed modern medicine, with platinum-based drugs (cisplatin, carboplatin, and oxaliplatin) serving as the foundation of metal-based cancer therapy. While these agents have shown impressive clinical efficacy, their effectiveness is limited by two major constraints, including their inherent toxicity profiles and resistance mechanisms related to their DNA-damaging mode of action.
This Special Issue presents the therapeutic potential of non-platinum transition metals—including, but not limited to, manganese, iron, cobalt, copper, ruthenium, osmium, gold, and iridium complexes—as innovative alternatives and complements. We welcome articles, communications, and reviews on inventive design strategies that exploit unique coordination chemistry with novel in vitro and/or in vivo mechanisms of action. By bridging molecular discovery and therapeutic potential, this collection aims to catalyze the development of metallodrugs with enhanced specificity and multimodal anticancer activity.
Dr. Wai Lun Man
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer drugs
- transition metal complexes
- inorganic chemistry
- medicinal chemistry
- chemotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
